What is AOD-9604?
AOD-9604 is a synthetic peptide fragment derived from the C-terminal region (amino acids 176-191) of human growth hormone (hGH). Originally developed by Metabolic Pharmaceuticals, it was designed to retain the fat-burning properties of growth hormone while eliminating the muscle-building and other anabolic effects. This selective action makes it an attractive option for targeted fat loss.
Selective Fragment
AOD-9604 contains only the fat-burning portion of growth hormone, avoiding the muscle-building and other systemic effects of full hGH.
Targeted Lipolysis
Specifically targets adipose tissue for fat breakdown and mobilization, promoting selective fat loss without affecting lean muscle mass.
Research and Potential Benefits
AOD-9604 works by stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat storage), leading to selective fat loss without affecting lean muscle mass.
- ✓ Lipolysis Stimulation: Activates hormone-sensitive lipase to break down stored triglycerides in adipose tissue.
- ✓ Lipogenesis Inhibition: Reduces the formation of new fat cells and limits fat storage in existing adipocytes.
- ✓ Selective Action: Targets adipose tissue specifically without affecting glucose metabolism or muscle anabolism.
Clinical studies and anecdotal reports suggest AOD-9604 can improve body composition by reducing fat mass while preserving lean muscle tissue.
- ✓ Abdominal Fat Reduction: Particularly effective at reducing visceral and subcutaneous abdominal fat deposits.
- ✓ Muscle Preservation: Maintains lean muscle mass during fat loss phases, improving body composition ratios.
- ✓ Metabolic Enhancement: May improve metabolic rate and fat oxidation capacity during exercise.
AOD-9604 has shown a favorable safety profile in clinical trials, with minimal side effects reported compared to full growth hormone therapy.
- ! Research Status: Currently available as a research peptide, not approved for human consumption by FDA.
- ! Minimal Side Effects: Generally well-tolerated with fewer side effects than full hGH therapy.
- ! Professional Guidance: Should be used under medical supervision as part of a comprehensive body composition program.
References & Citations
- Heffernan, M. A., et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182-5189. Source.
- Ng, F. M., et al. (2000). Growth hormone treatment of hypophysectomized rats increases the abundance of hepatic genes encoding lipogenic enzymes and growth hormone receptor. Endocrinology, 141(11), 4321-4327. Source.
- Metabolic Pharmaceuticals. (2004). AOD9604 Clinical Development Program. Company Research Documentation.

Ask Dr. John About AOD-9604
Get personalized clinical insights from Dr. Jobby John, PharmD, FACA. Ask specific questions about AOD-9604 and receive evidence-based answers from his extensive clinical experience.